Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
d-cycloserine + lurasidone
- Development stage
- Phase 3
- Lead developer
- NRx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**d-cycloserine + lurasidone** is an investigational oral fixed-dose combination developed as NRX-101 for severe bipolar depression with acute or subacute suicidal ideation or behavior. D-cycloserine is a dose-dependent N-methyl-D-aspartate receptor modulator, while lurasidone is an atypical antipsychotic whose principal pharmacology includes serotonin 5-HT2A and dopamine D2 receptor antagonism. The combination is intended to sustain antidepressant and antisuicidal effects while lurasidone may reduce D-cycloserine-associated psychomimetic effects. NRx Pharmaceuticals has also explored the product in treatment-resistant depression with transcranial magnetic stimulation, chronic pain, and complicated urinary tract infection including pyelonephritis. ([nrxpharma.com](https://www.nrxpharma.com/nrx-100-nrx-101/))
- Brand names
- Cyclurad
- Other names
- D-cycloserine/lurasidoneDCS/lurasidone
02
Targets
DRD2 (Dopamine D2 Receptor)GRIN1 (NMDA receptor subunit 1)HTR2A (Serotonin receptor 5-HT2A)DdlA (D-alanyl-D-alanine Synthetase)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on d-cycloserine + lurasidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on d-cycloserine + lurasidone.